Regenerative Medicine Promotion Act of 2011
Latest action · May 13, 2011 Referred to the Subcommittee on Health.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedMay 12, 2011
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Regenerative Medicine Promotion Act of 2011 - Requires the Comptroller General to submit to Congress a report identifying all ongoing federal programs and activities regarding regenerative medicine.
Directs the Secretary of Health and Human Services (HHS) to establish a Regenerative Medicine Coordinating Council in the Office of the Secretary, the duties of which shall include: (1) preparing a national strategy to support research into regenerative medicine and the development of drugs, biological products, medical devices, and biomaterials for use in regenerative medicine; (2) identifying sources of funding for research into regenerative medicine and areas where such funding is inadequate; and (3) making recommendations regarding federal policies to support development and marketing of regenerative medicine products.
Authorizes the Secretary, acting through the Director of the National Institutes of Health (NIH), to make grants for: (1) basic or preclinical research into regenerative medicine; (2) research and development of drugs, biological products, medical devices, and biomaterials for use in regenerative medicine; and (3) the making of an investigational new drug application or an investigational device exemption application within four years of receiving such grant.
Amends the Public Health Service Act to authorize the Director of NIH to award grants, contracts, or cooperative agreements to accelerate the development of high need cures through the development of medical products and behavioral therapies for use in regenerative medicine.
Authorizes the Secretary, acting through the Commissioner of Food and Drugs, to: (1) conduct, support, or collaborate in regulatory research to assist the Food and Drug Administration (FDA) in performing its functions with respect to regenerative medicine; or (2) make grants to fund regulatory research for such purpose.
Cosponsors 19
Members who signed on, in the order they did. Signatures ran from May 12, 2011 to Nov 13, 2012; 7 are original cosponsors, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-PA | Charles W. Dent | Original | May 12, 2011 |
| D-CO | Diana DeGette | Original | May 12, 2011 |
| D-NC | G. K. Butterfield | Original | May 12, 2011 |
| D-RI | James R. Langevin | Original | May 12, 2011 |
| R-PA | Jim Gerlach | Original | May 12, 2011 |
| D-OH | Marcia L. Fudge | Original | May 12, 2011 |
| D-NJ | Rush Holt | Original | May 12, 2011 |
| D-CA | Anna G. Eshoo | Jun 2, 2011 | |
| D-MA | Michael E. Capuano | Jun 21, 2011 | |
| R-OH | Steven C. LaTourette | Jun 21, 2011 | |
| D-CA | Sam Farr | Sep 21, 2011 | |
| D-MA | Barney Frank | Oct 6, 2011 | |
| D-MA | James P. McGovern | Oct 6, 2011 | |
| D-IL | Jesse L. Jackson, Jr. | Oct 6, 2011 | |
| R-TX | Michael C. Burgess | Dec 14, 2011 | |
| D-NJ | Steven R. Rothman | Apr 17, 2012 | |
| D-FL | Theodore E. Deutch | Apr 25, 2012 | |
| D-CT | Christopher Murphy | May 7, 2012 | |
| D-MD | Chris Van Hollen | Nov 13, 2012 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred May 12, 2011 |
| Health Subcommittee | Referred May 13, 2011 |
Actions 3
Everything that happened, newest first.
- May 13, 2011Referred to the Subcommittee on Health.
- May 12, 2011Introduced in House
- May 12, 2011Referred to the House Committee on Energy and Commerce.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the page H3280.
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To launch a national strategy to support regenerative medicine through funding for research and commercial development of regenerative medicine products and development of a regulatory environment that enables rapid approval of safe and effective products, and for other purposes.
- Short Titles as Introduced
- Regenerative Medicine Promotion Act of 2011
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Advisory bodies
- Department of Health and Human Services
- Drug safety, medical device, and laboratory regulation
- Executive agency funding and structure
- Genetics
- Health
- Health programs administration and funding
- Health technology, devices, supplies
- Medical research
- Product development and innovation
- Research administration and funding
- Research and development
Text 1
Each version as it was printed, newest first.
- May 12, 2011Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.
